Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer

@inproceedings{Tai2015EvaluationOS,
  title={Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer},
  author={Cheng-Jeng Tai and Chien-Kai Wang and Chen-Jei Tai and Ching Tzao and Yung-Chang Lien and Chih-Cheng Hsieh and Cheng-I Hsieh and Hong-cheng Wu and Chih-hsiung Wu and Chun-Chao Chang and Ray-Jade Chen and H H Chiou},
  booktitle={Medicine},
  year={2015}
}
Current chemotherapeutic regimens for nonsmall cell lung cancer (NSCLC) have reached a plateau over the last few years. Targeted therapy makes use of tyrosine kinase inhibitors (TKIs) to suppress a number of signaling pathways including epidermal growth factor receptor and vascular endothelial growth factor which are active in NSCLC biology. In this study, we used sunitinib, a multi-target receptor TKI, combined with chemotherapy for unresectable/metastatic NSCLC.This open label Simon's 2 stage… CONTINUE READING